A Laboratory Model To Explain the Survival Advantage Observed in Patients Taking Adjuvant Tamoxifen Therapy
- 1 January 1993
- book chapter
- Published by Springer Nature
- Vol. 127, 23-33
- https://doi.org/10.1007/978-3-642-84745-5_4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ miceEuropean Journal of Cancer and Clinical Oncology, 1990
- Prevention of breast cancer with tamoxifen—an update on the royal Marsden Hospital pilot programmeEuropean Journal of Cancer and Clinical Oncology, 1990
- Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifenJournal of Steroid Biochemistry, 1988
- Hormone Receptor Assays: Clinical Usefulness in the Management of Carcinoma of the BreastCRC Critical Reviews in Clinical Laboratory Sciences, 1988
- Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapyEuropean Journal of Cancer and Clinical Oncology, 1987
- Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic miceCancer Letters, 1980
- Oestrogen-responsive human breast cancer in long term tissue cultureNature, 1975
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971